

# FDA panel backs ketamine-like drug for depression

February 14 2019

---



(HealthDay)—An expert panel for the U.S. Food and Drug

Administration has endorsed a drug for major depressive disorder that is a close relative to ketamine.

If approved by the FDA, the new drug known as esketamine would be available to patients who have not found relief with at least two other antidepressants. The Tuesday vote was 14 to 2, with one member abstaining, according to *CNN*. The FDA does not have to follow the recommendations of its expert panels, but it typically does. A decision is expected in early March.

Made by Janssen, a division of Johnson & Johnson, esketamine is a nasal spray medication that targets different pathways in the brain than other antidepressants do. Unlike antidepressants that can take four to six weeks to take effect, esketamine's benefits can be felt within hours or days, the FDA said. Therefore, it is likely that esketamine might be used effectively in conjunction with an antidepressant, the agency added.

Despite the panel's approval, two of five key studies of esketamine failed to meet their primary goals. When taking esketamine, some patients experienced sedation, blood pressure spikes, and dissociation within two hours of taking the drug, *CNN* reported. Six patients died while taking esketamine in those trials, including three suicides, but agency documents concluded that "it is difficult to consider these deaths as drug-related." Because of those caveats, patients will not be allowed to purchase the [drug](#) at a local pharmacy; instead, a [health care](#) professional would have to monitor the person during the first two hours, the news service said.

**More information:** [CNN Article](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: FDA panel backs ketamine-like drug for depression (2019, February 14) retrieved 6 May 2024 from <https://medicalxpress.com/news/2019-02-fda-panel-ketamine-like-drug-depression.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.